Top

Current Hepatology Reports

Published in:

01-09-2017 | Hepatitis B (J Lim, Section Editor)

Epidemiology and Treatment of Hepatitis B in Prisoners

Authors: Jacob M. Smith, A. Ziggy Uvin, Alexandria Macmadu, Josiah D. Rich

Published in: Current Hepatology Reports | Issue 3/2017

Abstract

Purpose of Review

The review details recent literature reports regarding Hepatitis B Virus (HBV) and, in particular, Hepatitis B prevalence/incidence in incarcerated populations around the world. Furthermore, the review will summarize the national/international guidelines regarding HBV and look at diagnosis, vaccination, treatment, and linkage to care after release.

Recent Findings

HBV affects prisoners at a much higher rate than the general populations. Many who are at increased risk for HBV infection are also at increased risk for incarceration. Incarcerated settings also have higher rates of HBV transmission.

Summary

Incarcerated individuals should be immunized if they are not already immune to HBV. Increased access to safe injecting and tattoo paraphernalia, condoms, and personal hygiene equipment could reduce the spread of HBV and other blood-borne and sexually transmitted infections. Future research should focus on ways to prevent the spread of HBV and similar viruses in incarcerated settings in order to protect incarcerated individuals and the general public. Research on effective linkage to community HBV care following release is needed.

Hepatitis B. In: World Health Organization. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 30 May 2017.

GBD 2013 Mortality and Causes of Death Collaborators. “Global, Regional, and National Age-Sex Specific All-Cause and Cause-Specific Mortality for 240 Causes of Death, 1990–2013: A Systematic Analysis for the Global Burden of Disease Study 2013.” Lancet (London, England) 385, no. 9963 (January 10, 2015): 117–71. doi:10.1016/S0140-6736(14)61682-2 .

• Dolan K, Wirtz A, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388:1089–102. The report focuses on the challenges and opportunities that prison settings create for the prevention and treatment of HIV, viral hepatitis, and/or tuberculosis. CrossRefPubMed

•• Kamarulzaman A, Reid S, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016;388:1115–26. One of the several important reports that details the risk/prevalence of HIV, HBV, HCV, and Tuberculosis in prisons and comments on prevention strategies. CrossRefPubMed

• Rich J, Beckwith C, Macmadu A, et al. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. Lancet. 2016;388:1103–14. The review focuses on the clinical management of those with HIV, viral hepatitis, and/or tuberculosis in an incarcerated setting. CrossRefPubMedPubMedCentral

• Nelson N, Easterbrook P, McMahon B. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clinics in Liver Disease. 2016;20:607–28. The report details the success of preventing the spread of HBV by vaccinating high-risk adults and the difficulties associated with accessing and vaccinating this high-risk population. CrossRefPubMed

•• HBV FAQs for Health Professionals | Division of Viral Hepatitis | CDC. In: Cdc.gov. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm. Accessed 30 May 2017. The page provides a brief overview and gives statistics about acute and chronic HBV in the United States.

Harzke A, Goodman K, Mullen P, Baillargeon J. Heterogeneity in hepatitis B virus (HBV) seroprevalence estimates from US adult incarcerated populations. Ann Epidemiol. 2009;19:647–50.CrossRefPubMedPubMedCentral

Tresó B, Barcsay E, Tarján A, Horváth G, Dencs Á, Hettmann A, et al. Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary. Journal of Urban Health. 2011;89:108–16.CrossRefPubMedCentral

10.

Khajedaluee M, Babaei A, Vakili R, Valizade N, Homaei Shandiz F, Alavian S, et al. Sero-prevalence of blood-borne tumor viruses (HCV, HBV, HTLV-I and KSHV infections) and related risk factors among prisoners in Razavi Khorasan Province, Iran, in 2008. Hepat Mon. 2016; doi:10.5812/hepatmon.31541.

11.

• Prasetyo A, Dirgahayu P, Sari Y, Hudiyono H, Kageyama S. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia. The Journal of Infection in Developing Countries. 2013; doi:10.3855/jidc.2965. The report details the prevalence of HBV along with HIV, HCV, and HTLV-1/2 in inmates from central Javan prisons. The inmates were all known drug abusers.

12.

•• Keten D, Emin Ova M, Sirri Keten H, Keten A, Gulderen E, Tumer S, et al. The prevalence of hepatitis B and C among prisoners in Kahramanmaras, Turkey. Jundishapur Journal of Microbiology. 2016; doi:10.5812/jjm.31598. The report details the prevalence of HBV, HCV, and HIV in a prison population in Turkey and compares prevalence data to the demographics of the subjects.

13.

Bautista-Arredondo S, González A, Servan-Mori E, et al. A cross-sectional study of prisoners in Mexico City comparing prevalence of transmissible infections and chronic diseases with that in the general population. PLoS One. 2015;10:e0131718.CrossRefPubMedPubMedCentral

14.

• U.S. 2014 Surveillance Data for Viral Hepatitis | Statistics & Surveillance | Division of Viral Hepatitis | CDC. In: Cdc.gov. https://www.cdc.gov/hepatitis/statistics/2014surveillance/. Accessed 30 May 2017. The CDC page contains data regarding reported cases of HBV from 48 states and estimates the total number of acute cases of HBV infection in the United States.

15.

Transmission of Hepatitis B Virus in Correctional Facilities—Georgia, January 1999–June 2002. In: Cdc.gov. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5330a2.htm. Accessed 30 May 2017.

16.

Macalino G, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94:1218–23.CrossRefPubMedPubMedCentral

17.

Dana D, Zary N, Peyman A, Behrooz A. Risk prison and hepatitis B virus infection among inmates with history of drug injection in Isfahan, Iran. Sci World J. 2013;2013:1–4.CrossRef

18.

Gupta S, Altice F. Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. Journal of Urban Health. 2009;86:263–79.CrossRefPubMedPubMedCentral

19.

Infection control in prisons and places of detention - GOV.UK. In: Gov.uk. https://www.gov.uk/government/publications/infection-control-in-prisons-and-places-of-detention. Accessed 30 May 2017.

20.

Hepatitis B FAQs for the Public | Division of Viral Hepatitis | CDC. In: Cdc.gov. https://www.cdc.gov/hepatitis/hbv/bfaq.htm. Accessed 30 May 2017.

21.

• Rumble C, Pevalin D, O’Moore E. The wider impact of routine testing for blood borne viruses in prisons. Eur J Pub Health. 2015; doi:10.1093/eurpub/ckv175.236. The paper is a systematic review of blood-borne viruses in English prison populations. It reviews current testing policies for at-risk inmates and suggests areas of revision in regards to testing policies.

22.

Kavasery R, Maru D, Sylla L, Smith D, Altice F. A prospective controlled trial of routine opt-out HIV testing in a Men’s jail. PLoS One. 2009;4:e8056.CrossRefPubMedPubMedCentral

23.

Routine Jail-Based HIV Testing—Rhode Island, 2000–2007. In: Cdc.gov. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5924a3.htm. Accessed 30 May 2017.

24.

Geitona M, Milioni S. Health status and access to health services of female prisoners in Greece: a cross-sectional survey. BMC Health Serv Res. 2016; doi:10.1186/s12913-016-1506-3.

25.

Brown R, McMahon B, Lok A, Wong J, Ahmed A, Mouchli M, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2015;63:319–33.CrossRefPubMed

26.

•• Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. In: World Health Organization. http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/. Accessed 30 May 2017. The World Health Organization’s detailed report on how to prevent, care, and treat those with Chronic Hepatitis B infection.

27.

•• Sequera VCAD-G, Valencia S, García-Basteiro AL, Marco A, Bayas JM. Vaccinations in prisons: a shot in the arm for community health. Human Vaccines & Immunotherapeutics. 2015;11:2615–26. The report details the increased risk prisoners have for acquiring communicable diseases and how vaccination of prisoners can not only protect inmates but also benefit the general population. CrossRef

28.

A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. In: Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5516a1.htm. Accessed 30 May 2017.

29.

Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings. In: Cdc.gov.

30.

Charuvastra A, Stein J, Schwartzapfel B, Spaulding A, Horowitz E, Macalino G, et al. Hepatitis B vaccination practices in state and federal prisons. Public Health Rep. 2001;116:203–9.CrossRefPubMedPubMedCentral

31.

Hepatitis B Vaccination of Inmates in Correctional Facilities—Texas, 2000--2002. In: Cdc.gov.

32.

HUTCHINSON S, WADD S, TAYLOR A, BIRD S, MITCHELL A, MORRISON D, et al. Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. Vaccine. 2004;23:210–4.CrossRefPubMed

33.

Beck C, Cloke R, O’Moore É, Puleston R. Hepatitis B vaccination coverage and uptake in prisons across England and Wales 2003–2010: a retrospective ecological study. Vaccine. 2012;30:1965–71.CrossRefPubMed

34.

Ewaoche I, Otu-Bassey I, Nabagenyi M, Utsalo S. Prevalence and eligibility for treatment of chronic hepatitis B infection among prison inmates and female sex workers in Calabar, Cross River state, Nigeria. British Microbiology Research Journal. 2016;17:1–10.CrossRef

35.

Larney S, Monkley D, Indig D, Hampton S. A cross-sectional study of susceptibility to vaccine-preventable diseases among prison entrants in New South Wales. Med J Aust. 2013;198:376–9.CrossRefPubMed

36.

Rotily M, Vernay-Vaisse C, Bourliere M, Galinier-Pujol A, Rousseau S, Obadia Y. HBV and HIV screening, and hepatitis B immunization programme in the prison of Marseille, France. Int J STD AIDS. 1997;8:753–9.CrossRefPubMed

37.

Wakeman S. Medications for addiction treatment. J Addict Med. 2017;11:1–2.CrossRef

Title: Epidemiology and Treatment of Hepatitis B in Prisoners
Authors: Jacob M. Smith
A. Ziggy Uvin
Alexandria Macmadu
Josiah D. Rich
Publication date: 01-09-2017
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 3/2017
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-017-0364-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Epidemiology and Treatment of Hepatitis B in Prisoners

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2017

Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis

Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?

MELD-Na: Does This Leave Anyone Behind?

Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy

Autoimmune Sclerosing Cholangitis: a Review of the Overlap between Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Children

Idiopathic Non-cirrhotic Portal Hypertension and Close Entities: a Need for Clarifying Terminology

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page